Welcome Message

Dear Colleagues and Friends,

It gives me great pleasure to announce that the 17th annual scientific session of China InterventionaTherapeutics (CIT) 2019 in partnership with TCT, which will be held on Thursday, March 28 through Sunday, March 31, 2019 will move back to Beijing, capital city of China. It will take place at the China National Convention Center (CNCC). CIT2019 is organized by the Chinese Medical Association, co-sponsored by National Center for Cardiovascular Diseases of China, CIT Board of Directors, Chinese Society of Cardiology, and Cardiovascular Research Foundation, co-organized by Fu Wai Hospital, Chinese Academy of Medical Sciences and supported by 35 international and national societies and well-known heart centers.

CIT2019 will continue to focus on C-Cooperation, I-Innovation, and T-Transition. Under the core concept and direction, CIT 2019 will offer 1400+ didactic presentations, 600+ clinical cases, and 40+ live cases in its threeand- half-day program. The grand opening and plenary session will take place in the morning on Friday, March 29, 2019. Original researches are presented in the forms of oral and poster abstracts, late-breaking clinical trials, topic-oriented symposia, workshops, and concurrent sessions. Basic research, practical interventional techniques, interventional pharmacology, cardiovascular prevention, and cardiovascular imaging are also covered in-depth. CIT will make an effort to minimize gaps between evidence and practice, and to facilitate and accelerate the incorporation into clinical practice of new therapies with proven safety and efficacy in appropriately conducted clinical trials. The transition theme of CIT also highlights the current and future expansion of interventional cardiovascular practice from treatment of obstructive vascular disease to other common cardiovascular problems including structural heart disease (e.g. aortic stenosis), atrial fibrillation and hypertension.

As the largest interventional cardiology meeting in Asia-Pacific region, it is expected that more than 8,000 experts, cardiologists, radiologists, vascular medicine specialists, industrial partners and other health care professionals with a special interest in the field of interventional cardiology will attend the meeting. Participants will have the opportunities to share scientific information and the latest advances, to exchange expertise in interventional cardiology, to renew our friendship, and to increase worldwide collaboration. CIT2019 will also provide a unique opportunity for the industries to exhibit their new products and to contact with the cardiologists more closely.

I look forward to your active participations in CIT2019 in partnership with TCT in Beijing!

Sincerely Yours,

Runlin Gao, MD, FACC, FESC, FSCAI

Professor of Medicine

Chairman, China Interventional Therapeutics (CIT)